详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

The efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer

84| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China. [2]Reproductive Medicine Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China. [3]Department of Gynecology and Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [4]Cancer Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China.

出处：

DOI：

ISSN：

关键词： Ovarian cancer immune checkpoint tumor microenvironment immune checkpoint inhibitors (ICIs) targeted therapy

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版中科院分区表Review为是的期刊

：

大类 | 2 区医学

小类 | 2 区生化与分子生物学 2 区医学：研究与实验

最新[2025]版

：

大类 | 3 区医学

小类 | 3 区生化与分子生物学 3 区医学：研究与实验

JCR分区：

出版当年[2021]版：

Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 4.5 最新[2023版] 5.6 最新五年平均 7.615 出版当年[2021版] 7.261 出版当年五年平均 5.6 出版前一年[2020版] 6.2 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China.

通讯作者：

通讯机构： [4]Cancer Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China. [*1]Cancer Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,1095 Jiefang Avenue,Wuhan 430030,China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]恶性肿瘤患者基于临床和血液学标记物的免疫检查点抑制剂相关不良事件预测模型的建立 [2]恶性肿瘤患者基于临床和血液学标记物的免疫检查点抑制剂相关不良事件预测模型的建立 [3]Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy [4]Immune Checkpoint and Other Receptor-Ligand Pairs Modulating Macrophages in Cancer: Present and Prospects [5]ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas [6]Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma [7]PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities [8]Advances of Targeted Therapy for Hepatocellular Carcinoma [9]Immunotherapy for NSCLC with oncogenic driver variants [10]Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment